Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of DA-5216 and DA-5216-R in Healthy Adults
NCT05506007Phase 1Unknown
- Sponsor
- Dong-A ST
- Start
- Aug 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azilsartan in hypertension (HTN) (4 arms), sponsored by Dong-A ST. Primary endpoints: Peak Plasma Concentration and Area under the plasma concentration versus time curve. Status: unknown.
02
Drugs
azilsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05506007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05506007.